如何破除益生菌市场乱象,让大众更好的了解益生菌产品?(综述)
  • 菌群研究的进展促进了益生菌产业的发展,但由于监管等问题,对益生菌产品健康益处的声明目前仍存在乱象,这不仅对医生和消费者造成困扰,也为开展相关研究带来阻碍;
  • 为解决这一问题,需要联合学术界、专业组织和产业界,建立没有利益冲突的专业机构,采用GRADE分析评估益生菌产品临床益处的证据等级,严格评价产品质量,并公开相关信息供大众参考;
  • 这将有助于益生菌企业和产品获得大众信任,构建更好的市场秩序。
主编推荐语
mildbreeze
Gastroenterology近期发表的综述,回顾了益生菌的发展历史,介绍了益生菌产品的监管分类,针对如何改善目前益生菌产品健康益处声明中存在的问题,提出了一种解决方案,希望能够促进开展高质量的益生菌研究,增加公众信任,改善市场秩序。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Gastroenterology [IF:33.883]

Probiotics and the Microbiome: How can we help patients make sense of probiotics?

益生菌与微生物组:我们如何帮助患者理解益生菌?

10.1053/j.gastro.2020.11.047

2020-12-08, Review

Abstract & Authors:展开

Abstract:收起
The notion of probiotics as microbes that confer health benefits has its origins in the speculative ideas that are more than a century old, yet remain largely unsubstantiated by scientific evidence. The recent advances in microbiome science have highlighted the importance of intestinal microbes in human physiology and disease pathogenesis. These developments have provided a boost to the probiotics industry, which continues to experience exponential growth driven mainly by creative marketing. Consumers, patients, and most health care providers are not able to discern the underlying science or differentiate the permitted claims that promise vague health benefits from disease-specific claims reserved for drugs. No probiotic product has been able to satisfy the regulatory requirements to be categorized as a drug, a substance intended to cure, mitigate, or prevent disease. However, patients take probiotic products in the belief that they will help to treat their intestinal or systemic diseases. Thus far, the regulators have failed to create policies that would assist to inform the public in this area. In fact, the existing regulatory regime actually creates formidable barriers to research that could provide evidence for clinical efficacy of probiotic products. We propose a potential solution to this vexing problem, where a committee created through a partnership of academia, professional organizations, and industry, but free of potential conflicts of interest, would be charged with rigorous evaluation of specific probiotic products and the evidence in support of their different claims. Companies that would submit to this process would earn the trust of consumers and healthcare providers, as well as a distinction in the marketplace.

First Authors:
Robert A Britton,Diane E Hoffmann,Alexander Khoruts

Correspondence Authors:
Alexander Khoruts

All Authors:
Robert A Britton,Diane E Hoffmann,Alexander Khoruts

评论